Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure
- 1 November 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 31 (11) , 2300-2308
Abstract
Objectives: Enhanced central sympathetic outflow is an indicator of the prognosis of heart failure. Although the central sympatholytic drug moxonidine is an established therapeutic strategy for hypertension, its benefits for hypertensive heart failure are poorly understood. In the present study, we investigated the effects of central sympathoinhibition by intracerebral infusion of moxonidine on survival in a rat model of hypertensive heart failure and the possible mechanisms involved. Methods and results: As a model of hypertensive heart failure, we fed Dahl salt-sensitive rats an 8% NaCl diet from 7 weeks of age. Intracerebroventricular (ICV) infusion of moxonidine (moxonidine-ICV-treated group [Mox-ICV]) or vehicle (vehicle-ICV-treated group [Veh-ICV]) was performed at 14–20 weeks of age, during the increased heart failure phase. Survival rates were examined, and sympathetic activity, left ventricular function and remodelling, and brain oxidative stress were measured. Hypertension and left ventricular hypertrophy were established by 13 weeks of age. At around 20 weeks of age, Veh-ICV rats exhibited overt heart failure concomitant with increased urinary norepinephrine (uNE) excretion as an index of sympathetic activity, dilated left ventricle, decreased percentage fractional shortening, and myocardial fibrosis. Survival rates at 21 weeks of age (n = 28) were only 23% in Veh-ICV rats, and 76% (n = 17) in Mox-ICV rats with concomitant decreases in uNE, myocardial fibrosis, collagen type I/III ratio, brain oxidative stress, and suppressed left ventricular dysfunction. Conclusion: Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure. Central sympathoinhibition can be effective for the treatment of hypertensive heart failure.Keywords
This publication has 39 references indexed in Scilit:
- Pharmacological Properties of the Central Antihypertensive Agent, MoxonidineCardiovascular Therapeutics, 2011
- Imidazoline Antihypertensive Drugs: Selective I1‐Imidazoline Receptors ActivationCardiovascular Therapeutics, 2011
- Sympathetic Neural Activity in Hypertension and Related DiseasesAmerican Journal of Hypertension, 2010
- Therapeutic strategies for targeting excessive central sympathetic activation in human hypertensionExperimental Physiology, 2010
- Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidineNeuroscience, 2005
- Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five yearsJACC, 2004
- Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trialAmerican Heart Journal, 2004
- Imidazoline antihypertensive drugs: a critical review on their mechanism of actionPharmacology & Therapeutics, 2002
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- Risk Factors for Congestive Heart Failure in US Men and WomenArchives of internal medicine (1960), 2001